Preventive Effect of Poricoic Acid against Nonalcoholic Steatohepatitis |
Kim, Hae Ran
(Division of Longevity and Biofunctional Medicine, School of Korean Medicine, Pusan National University)
Jung, Dae Young (Division of Longevity and Biofunctional Medicine, School of Korean Medicine, Pusan National University) Kim, Say (Division of Longevity and Biofunctional Medicine, School of Korean Medicine, Pusan National University) Jung, Myeong Ho (Division of Longevity and Biofunctional Medicine, School of Korean Medicine, Pusan National University) |
1 | Sheka, A. C., Adeyi O., Thompson J., Hameed, B., Crawford, P. A. and Ikramuddin, S. 2020. Nonalcoholic Steatohepatitis. JAMA. 323, 1175-1183. DOI |
2 | Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M. and Sanyal, A. J. 2018. Mechanisms of NAFLD development and therapeutic strategies. Nat. Med. 24, 908-922. DOI |
3 | Ipsen, D. H., Lykkesfeldt, J. and Tveden-Nyborg, P. 2018. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cell. Mol. Life Sci. 75, 3313-3327. DOI |
4 | Kim, J. H., Sim, H. A., Jung, D. Y., Lim, E. Y., Kim, Y. T., Kim, B. J. and Jung, M. H. 2019. Poria cocus wolf extract ameliorates hepatic steatosis through regulation of lipid metabolism, inhibition of ER stress, and activation of autophagy via AMPK activation. Int. J. Mol. Sci. 20, 4801. DOI |
5 | Li, Q., Ming, Y., Jia, H. and Wang, G. 2021. Poricoic acid A suppresses TGF-β1-induced renal fibrosis and proliferation via the PDGF-C, Smad3 and MAPK pathways. Exp. Ther. Med. 21, 289. DOI |
6 | Chen, D. Q., Feng, Y. L., Chen, L., Liu, J. R., Wang, M., Vaziri, N. D. and Zhao, Y. Y. 2019. Poricoic acid A enhances melatonin inhibition of AKI-to-CKD transition by regulating Gas6/AxlNFκB/Nrf2 axis. Free Radic. Biol. Med. 134, 484-497. DOI |
7 | Kikuchi, T., Uchiyama, E., Ukiya, M., Tabata, K., Kimura, Y., Suzuki, T. and Akihisa, T. 2011. Cytotoxic and apoptosis-inducing activities of triterpene acids from Poria cocos. J. Nat. Prod. 74, 137-144. DOI |
8 | Nagappan, A., Jung, D. Y., Kim, J. H., Lee, H. and Jung, M. H. 2018. Gomisin N Alleviates ethanol-induced liver injury through ameliorating lipid metabolism and oxidative stress. Int. J. Mol. Sci. 19, 2601. DOI |
9 | Rios, J. L. 2011. Chemical constituents and pharmacological properties of Poria cocos. Planta Med. 77, 681-691. DOI |
10 | Schwabe, R. F., Tabas, I. and Pajvani, U. B. 2020. Mechanisms of fibrosis development in nonalcoholic steatohepatitis. Gastroenterology 158, 1913-1928. DOI |
11 | Zhang, C. and Yang, M. 2021. Current options and future directions for NAFLD and NASH treatment. Int. J. Mol. Sci. 22, 7571. DOI |
12 | Nie, A., Chao, Y., Zhang, X., Jia, W., Zhou, Z. and Zhu, C. 2020. Phytochemistry and pharmacological activities of Wolfiporia cocos (F.A. Wolf) Ryvarden & Gilb. Front. Pharmacol. 11. 505249. DOI |
13 | Powell, E. E., Wong, V. W. and Rinella, M. 2021. Non-alcoholic fatty liver disease. Lancet 397, 2212-2224. DOI |
14 | Schuster, S., Cabrera, D., Arrese, M. and Feldstein, A. E. 2018. Triggering and resolution of inflammation in NASH. Nat. Rev. Gastroenterol. Hepatol. 15, 349-364. DOI |
15 | Tanaka, N., Aoyama, T., Kimura, S. and Gonzalez, F. J. 2017. Targeting nuclear receptors for the treatment of fatty liver disease. Pharmacol. Ther. 179,142-157. DOI |